A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Rocapuldencel-T (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Argos Therapeutics Inc
- 25 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History